← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV21행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTPhase 2
ALT-803 (ALT-803)
ImmunityBio, Inc.·Acute Myeloid Leukemia
ORR 33%
Overview
Program
ALT-803
Overview
Company
ImmunityBio, Inc.
Overview
Modality
CGT
Overview
Target
Acute Myeloid Leukemia
Overview
Indication
Melanoma
Overview
Phase
PHASE_2
Overview
Status
DISCONTINUED
MoA
Mechanism
and efficacy data of different vaccine platforms
MoA
Biomarker
PD-L1 expression
PK/PD
Species
Macaque, Mouse
PK/PD
Animal (cat.)
Mouse
PK/PD
Experiment
Pharmacokinetic
Toxicology
Species
Macaque, Mouse
Toxicology
Animal (cat.)
Mouse
Toxicology
Major finding
First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer.. Cytokine induced memory-like natural killer (CIML NK) cells combined with an IL-15 super-agonist (N-803) are a novel modality to treat relapsed/refractory head and neck cancer. We report data from a phase I trial of haploidentical CIML NK cells combined with N-803 wi…
Clinical
Primary efficacy
ORR 33%
Clinical
ORR
80%
Clinical
Result source
ClinicalTrials.gov NCT02384954
Clinical
Data Tier / Score
A · 25
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 12일 (1일 전)